Robert A. Copeland, Chief Scientific Officer, to provide major symposium presentation on inhibition of key RNA-modifying enzymes as precision cancer therapeutics Preclinical data validate DHX9 as a new target in breast cancer and other solid tumors with loss-of-function mutations in the…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.